North America Blood Glucose Monitoring Market Size & Share Analysis - Growth Trends & Forecasts (2023 - 2028)

The North America Blood Glucose Monitoring Market is segmented by Type (Self-monitoring Blood Glucose, and Continuous Glucose Monitoring), Component (Glucometer Devices, Test Strips, Lancets, Sensors, and Durables), and Geography. The report offers market size and forecasts for all the above segments in value (USD billion), and volume.

INSTANT ACCESS

Home Market Analysis Healthcare Research Medical Devices Research Diagnostic Devices Research Clinical Diagnostic Devices Research Monitoring Devices Research Single time Monitoring Devices Research North America Blood Glucose Monitoring Market

North America Blood Glucose Monitoring Market Size

North America Blood Glucose Monitoring Market Size
Study Period 2018 - 2028
Base Year For Estimation 2021
Forecast Data Period 2023 - 2028
Market Size (2023) USD 13.71 Billion
Market Size (2028) USD 25.40 Billion
CAGR (2023 - 2028) 13.13 %

Major Players

North America Blood Glucose Monitoring Market

*Disclaimer: Major Players sorted in no particular order
setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

North America Blood Glucose Monitoring Market Analysis

The North America Blood Glucose Monitoring Market size is estimated at USD 13.71 billion in 2023, and is expected to reach USD 25.40 billion by 2028, growing at a CAGR of 13.13% during the forecast period (2023-2028).

In North America, diabetes incidence for Type-2 diabetes and other diabetes forms was numerically higher in individuals with COVID-19. Insulin resistance and impaired insulin secretion have been described in individuals without diabetes history who recovered from SARS-CoV-2 infections. It has been suggested that diagnosis and treatment of post-COVID-19 syndrome require integrated rather than disease-specific approaches.

Over the past decade, there has been a tremendous increase in the diabetic population globally. Several reports and surveys documented a drastic increase in the diabetic population based on the changes in lifestyles and habits. The growing diabetic population drives blood monitoring devices, such as CGM. Nearly 90% of Type-1 diabetic patients in developed countries use a glucometer. Nearly 50% of Type-2 patients are expected to use a glucometer during the forecast period.

North America dominates the global insulin therapeutics market, owing to the high prevalence of diabetes in the region because of the sedentary lifestyle and the launch of new drugs. The United States is expected to grow tremendously during the forecast period, owing to factors such as the high prevalence of obesity and increasing awareness regarding diabetes care in the region.

Therefore, owing to the factors mentioned above, the studied market is anticipated to witness growth over the analysis period.

North America Blood Glucose Monitoring Market Trends

This section covers the major market trends shaping the North America Blood Glucose Monitoring Market according to our research experts:

Continuous Glucose Monitoring Holds Highest Market Share in Europe Blood Glucose Monitoring Market.

CGMs are used to deliver a further descriptive picture of blood glucose patterns and trends than what may be achieved by traditional routine checking of glucose levels at set intervals. The current CGM devices can either retrospectively display the trends in blood glucose levels by downloading the data or give a real-time picture of glucose levels through receiver displays. Mostly real-time CGMs may offer an alert to patients, parents, or caregivers during actual or pending glycemic visits to facilitate timely management of blood glucose. This factor, along with the fact that CGM devices are becoming cheaper with the advent of new technologies, like cell phone integration, the CGM market is expected to witness steady growth during the forecast period.

The use of CGM by Type-1 diabetic patients is very less as compared to Type-2 diabetic patients. However, the expenditure incurred by Type-1 diabetic patients on these devices is nearly double that of Type-2 diabetics. The Abbott Freestyle Libre and the Dexcom G6's newest CGM models overcame many technical barriers. However, high costs and uncertainties about their efficacy and necessity kept CGM from widely used by people with Type-2 diabetes. Moreover, to lower the cost burden of diabetic patients in the United States, Abbott introduced a new, lower-priced category with Libre, at around USD 75 to USD 150 each month (two sensors that last 14 days each).

The rise in national awareness of diabetes is anticipated to drive the adoption of both SMBGs and CGMs on account of the prognostic and diagnostic treatment of diabetes.

North America Blood Glucose Monitoring Market_trends1

The United States is Expected to Dominate the North America Blood Glucose Monitoring Market.

In the United States, the prevalence of diabetes increased dramatically in the last two decades, a fact driven by the increased prevalence of obesity and lifestyle changes. Diabetes ranks among the fast-growing chronic diseases in the United States. About 1.75 million US citizens are diagnosed with diabetes every year. The country also has the highest obese population, which is a prominent cause of Type-2 diabetes.

In the United States, there are several innovations by startups, like Glooko, OneDrop, Verily, Vacate, Insulet, Noom, Bigfoot Biomedical, Virta Health, and Diabeloop, Orgenesis launched in the market.

The market for diabetes care devices is expected to experience steady growth due to the greater prevalence of obesity, owing to less physical activity, unhealthy food habits, and other lifestyle factors. Abbott and Dexcom received FDA approval to use continuous glucose monitoring in US hospitals for COVID-19-affected people. Dexcom began shipping CGMs to hospitals in April 2020. It plans to make 100,000 sensors for hospitals at low costs. The company plans to donate 10,000 phones and CGM readers to hospitals for scanning those sensors.

The growing awareness among people regarding advanced diabetes care products may positively impact the North American diabetes care devices market in the future.

North America Blood Glucose Monitoring Market_Country

North America Blood Glucose Monitoring Industry Overview

The blood glucose monitoring market is highly fragmented, with few major manufacturers present in the market. The CGM devices market is dominated by a few major players, like Dexcom, Medtronics, Abbott, and Senseonics. The market for BGM devices comprises more generic players like Roche, LifeScan, Arkray, Ascensia, etc. Technological innovations in the recent past helped the companies to strengthen their market presence.

North America Blood Glucose Monitoring Market Leaders

  1. Dexcom

  2. Johnson & Johnson

  3. Medtronics

  4. F. Hoffmann-La Roche AG

  5. Abbott Diabetes Care

*Disclaimer: Major Players sorted in no particular order

Dexcom, Johnson & Johnson, Medtronics, F. Hoffmann-La Roche AG, Abbott Diabetes Care
Need More Details on Market Players and Competitors?
Download PDF

North America Blood Glucose Monitoring Market News

  • In March 2022, Dexcom released G7 first in the United Kingdom and would expand the launch across Europe throughout 2022. Meanwhile, the CGM system is currently under review by the Food and Drug Administration for an eventual United States release.
  • In February 2021, Roche announced the launch of the new Accu-Chek Instant system, a new "connected" blood glucose monitoring (BGM) system, which could support and enable Roche's approach of integrated Personalised Diabetes Management (iPDM). Accu-Chek Instant could feature Bluetooth-enabled connectivity to the mySugr app, allowing wireless transfer of blood glucose results to the mySugr app.

North America Blood Glucose Monitoring Market Report - Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

    3. 4.3 Market Restraints

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products and Services

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. Market Segmentation

    1. 5.1 By Type

      1. 5.1.1 Self-monitoring Blood Glucose Devices

        1. 5.1.1.1 By Component (Value and Volume, 2016 - 2027)

          1. 5.1.1.1.1 Glucometer Devices

          2. 5.1.1.1.2 Test Strips

          3. 5.1.1.1.3 Lancets

      2. 5.1.2 By Continuous Glucose Monitoring

        1. 5.1.2.1 By Component (Value and Volume, 2016 - 2027)

          1. 5.1.2.1.1 Sensors

          2. 5.1.2.1.2 Durables

    2. 5.2 By Geography

      1. 5.2.1 United States (Value and Volume, 2016 - 2027)

        1. 5.2.1.1 Self-monitoring Blood Glucose

          1. 5.2.1.1.1 By Component (Glucometer Device, Test strips, Lancets)

        2. 5.2.1.2 Continuous Glucose Monitoring

          1. 5.2.1.2.1 By Component (Sensors and Durables)

      2. 5.2.2 Canada (Value and Volume, 2016 - 2027)

        1. 5.2.2.1 Self-monitoring Blood Glucose

          1. 5.2.2.1.1 By Component (Glucometer Device, Test strips, Lancets)

        2. 5.2.2.2 Continuous Glucose Monitoring

          1. 5.2.2.2.1 By Component (Sensors and Durables)

      3. 5.2.3 Rest of North America (Value and Volume, 2016 - 2027)

        1. 5.2.3.1 Self-monitoring Blood Glucose

          1. 5.2.3.1.1 By Component (Glucometer Device, Test strips, Lancets)

        2. 5.2.3.2 Continuous Glucose Monitoring

          1. 5.2.3.2.1 By Component (Sensors and Durables)

  6. 6. MARKET INDICATORS

    1. 6.1 Type-1 Diabetes Population (2016 - 2027)

    2. 6.2 Type-2 Diabetes Population (2016 - 2027)

  7. 7. COMPETITIVE LANDSCAPE

    1. 7.1 Company Profiles

      1. 7.1.1 Abbott Diabetes Care

      2. 7.1.2 F. Hoffmann-La Roche AG

      3. 7.1.3 Johnson & Johnson

      4. 7.1.4 Dexcom

      5. 7.1.5 Medtronic

      6. 7.1.6 Arkray

      7. 7.1.7 Ascensia Diabetes Care

      8. 7.1.8 Agamatrix Inc.

      9. 7.1.9 Bionime Corporation

      10. 7.1.10 Acon

      11. 7.1.11 Medisana

      12. 7.1.12 Trivida

      13. 7.1.13 Rossmax

  8. 8. MARKET OPPORTUNITIES AND FUTURE TRENDS

You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

North America Blood Glucose Monitoring Industry Segmentation

The North American blood glucose monitoring market is expected to register a CAGR greater than 8% over the forecast period. The North American blood glucose monitoring market is segmented by type (self-monitoring blood glucose and continuous glucose monitoring), component (glucometer devices, test strips, lancets, sensors, and durables), and geography. The report offers market size and forecasts for all the above segments in value (USD billion) and volume.

By Type
Self-monitoring Blood Glucose Devices
By Component (Value and Volume, 2016 - 2027)
Glucometer Devices
Test Strips
Lancets
By Continuous Glucose Monitoring
By Component (Value and Volume, 2016 - 2027)
Sensors
Durables
By Geography
United States (Value and Volume, 2016 - 2027)
Self-monitoring Blood Glucose
By Component (Glucometer Device, Test strips, Lancets)
Continuous Glucose Monitoring
By Component (Sensors and Durables)
Canada (Value and Volume, 2016 - 2027)
Self-monitoring Blood Glucose
By Component (Glucometer Device, Test strips, Lancets)
Continuous Glucose Monitoring
By Component (Sensors and Durables)
Rest of North America (Value and Volume, 2016 - 2027)
Self-monitoring Blood Glucose
By Component (Glucometer Device, Test strips, Lancets)
Continuous Glucose Monitoring
By Component (Sensors and Durables)
Need A Different Region Or Segment?
Customize Now

North America Blood Glucose Monitoring Market Research FAQs

The North America Blood Glucose Monitoring Market size is expected to reach USD 13.71 billion in 2023 and grow at a CAGR of 13.13% to reach USD 25.40 billion by 2028.

In 2023, the North America Blood Glucose Monitoring Market size is expected to reach USD 13.71 billion.

Dexcom, Johnson & Johnson, Medtronics, F. Hoffmann-La Roche AG and Abbott Diabetes Care are the major companies operating in the North America Blood Glucose Monitoring Market.

North America Blood Glucose Monitoring Industry Report

Statistics for the 2023 North America Blood Glucose Monitoring market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. North America Blood Glucose Monitoring analysis includes a market forecast outlook to 2028 and historical overview. Get a sample of this industry analysis as a free report PDF download.

North America Blood Glucose Monitoring Report Snapshots

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!